GB201900530D0 - Bicyclic peptide ligands specific for CD38 - Google Patents
Bicyclic peptide ligands specific for CD38Info
- Publication number
- GB201900530D0 GB201900530D0 GBGB1900530.5A GB201900530A GB201900530D0 GB 201900530 D0 GB201900530 D0 GB 201900530D0 GB 201900530 A GB201900530 A GB 201900530A GB 201900530 D0 GB201900530 D0 GB 201900530D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1900530.5A GB201900530D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for CD38 |
| JP2021541187A JP2022517399A (ja) | 2019-01-15 | 2020-01-15 | Ｃｄ３８に特異的な二環式ペプチドリガンド |
| EP20701838.3A EP3911366A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for cd38 |
| PCT/GB2020/050074 WO2020148530A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for cd38 |
| US17/422,943 US20220133733A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for cd38 |
| CN202080021078.5A CN113597317A (zh) | 2019-01-15 | 2020-01-15 | Cd38特异性的双环肽配体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1900530.5A GB201900530D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for CD38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201900530D0 true GB201900530D0 (en) | 2019-03-06 |
Family
ID=65528178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1900530.5A Ceased GB201900530D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for CD38 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220133733A1 (https=) |
| EP (1) | EP3911366A1 (https=) |
| JP (1) | JP2022517399A (https=) |
| CN (1) | CN113597317A (https=) |
| GB (1) | GB201900530D0 (https=) |
| WO (1) | WO2020148530A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| GB202016331D0 (en) * | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| CN118388598A (zh) * | 2024-04-22 | 2024-07-26 | 苏州大学附属第一医院 | 标记前体、探针及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004052404A2 (en) * | 2002-12-12 | 2004-06-24 | Tel Aviv University Future Technology Development L.P. | Glycogen synthase kinase-3 inhibitors |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| JP6807831B2 (ja) * | 2014-05-21 | 2021-01-06 | エントラーダ セラピューティクス，インコーポレイテッド | 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法 |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| CN107810190A (zh) * | 2015-04-28 | 2018-03-16 | 洛桑联邦政府综合工科学校（Epfl) | 酶活化因子XII (FXIIa)的新型抑制剂 |
| EP3645549A1 (en) * | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
-
2019
- 2019-01-15 GB GBGB1900530.5A patent/GB201900530D0/en not_active Ceased
-
2020
- 2020-01-15 CN CN202080021078.5A patent/CN113597317A/zh active Pending
- 2020-01-15 WO PCT/GB2020/050074 patent/WO2020148530A1/en not_active Ceased
- 2020-01-15 JP JP2021541187A patent/JP2022517399A/ja active Pending
- 2020-01-15 EP EP20701838.3A patent/EP3911366A1/en not_active Withdrawn
- 2020-01-15 US US17/422,943 patent/US20220133733A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220133733A1 (en) | 2022-05-05 |
| WO2020148530A1 (en) | 2020-07-23 |
| EP3911366A1 (en) | 2021-11-24 |
| CN113597317A (zh) | 2021-11-02 |
| JP2022517399A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201900530D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201900529D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| IL290089A (en) | Heterotandem bicyclic peptide complexes | |
| IL287881A (en) | Ox40-specific bicyclic peptide ligands | |
| LT4464721T (lt) | Heterotandeminiai dicikliniai peptidų kompleksai | |
| GB201900525D0 (en) | Bicyclic peptide ligands specific for caix | |
| GB201900526D0 (en) | Bicyclic peptide ligands specific for caix | |
| GB201820325D0 (en) | Bicyclic peptide ligands specific for psma | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201800593D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| GB201918495D0 (en) | Bicyclic peptide ligands specific for il-46 | |
| GB201904632D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201800610D0 (en) | Bicylic peptide ligands specific for CD38 | |
| GB201918488D0 (en) | Bicyclic peptide ligands specific for chymase | |
| GB201818499D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201815684D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201918559D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201918558D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201918557D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201701834D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| GB201918497D0 (en) | Bicyclic peptide ligands specific for klk7 | |
| GB201905631D0 (en) | Bicyclic peptide ligands specific for pd-l1 | |
| GB201904622D0 (en) | Bicyclic peptide ligands specific for pd-l1 | |
| GB201904621D0 (en) | Bicyclic peptide ligands specific for PD-L1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |